Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. Among the surgical and nonsurgical treatments available, radiofrequency ablation (RFA) and sorafenib have been shown to have efficacy. There is little evidence whether combination of these therapies would have additional benefits.
Methods
In a mouse model of HCC, effects of sorafenib were determined by tumor size, RFA-induced necrosis area (triphenyltetrazolium chloride staining), microvascular density (MVD; 4’,6-diamidino-2-phenylindole and anti-CD31 antibody staining), and tumor perfusion (magnetic resonance imaging).
Results
The RFA-induced necrosis area was 80.98 ± 9.14 and 69.49 ± 7.46 mm2 in mice administered 80 and 40 mg/kg sorafenib, respectively, but only 57.29 ± 3.39 mm2 in controls. Sorafenib also reduced tumor volume and enhanced RFA-induced tumor destruction in a dose-dependent manner, and reduced both MVD and tumor perfusion.
Conclusions
The results of our study suggest a potential role for combining RFA with sorafenib for treatment of HCC. Sorafenib could enhance RFA efficiency, possibly through its angiogenesis suppressive effects.
Get full access to this article
View all access options for this article.
References
1.
ZiemlewiczTJWellsSALubnerMGBraceCLLeeFTJrHinshawJLHepatic Tumor Ablation. Surg Clin North Am. 2016;96 (2):315–339.
2.
ZorbasGSamarasTA study of the sink effect by blood vessels in radiofrequency ablation. Comput Biol Med. 2015;57:182–186.
3.
ShenPFlemingSWestcottCChallaVLaparoscopic radiofrequency ablation of the liver in proximity to major vasculature: effect of the Pringle maneuver. J Surg Oncol. 2003;83 (1):36–41.
4.
Hines-PeraltaASukhatmeVReganMSignorettiSLiuZJGoldbergSNImproved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology. 2006;240 (1):82–89.
5.
MannCDMetcalfeMSLloydDMMaddernGJDennisonARThe safety and efficacy of ablative techniques adjacent to the hepatic vasculature and biliary system. ANZ J Surg. 2010;80 (1-2):41–49.
6.
El-SeragHBRudolphKLHepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132 (7):2557–2576.
7.
HorkanCAhmedMLiuZRadiofrequency ablation: Effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model. J Vasc Interv Radiol. 2004;15 (3):269–274.
8.
ShiraishiRYamasakiTSaekiIPilot study of combination therapy with transcatheter arterial infusion chemotherapy using iodized oil and percutaneous radiofrequency ablation during occlusion of hepatic blood flow for hepatocellular carcinoma. Am J Clin Oncol. 2008;31 (4):311–316.
9.
LlovetJMRicciSMazzaferroVet al;SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359 (4):378–390.
10.
CabibboGPettaSMaidaMCammàCSorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. Dig Dis. 2015;33 (5):668–674.
11.
Gadaleta-CaldarolaGInfusinoSDivellaRSorafenib: 10 years after the first pivotal trial. Future Oncol. 2015;11 (13):1863–1880.
12.
WelkerMWTrojanJAntiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res. 2013;5:337–347.
13.
ChoiJIImagawaDKBhosalePBhargavaPTirkesTSeeryTEMagnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib. Clinical and molecular hepatology. 2014;20:218–22.
14.
BruixJRaoulJLShermanMEfficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57 (4):821–829.
15.
FengXXuRDuXCombination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol. 2014;109 (12):1891–1899.
16.
KanXJingYWanQYSorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2015;19 (2):247–255.
LuDSRamanSSVodopichDJWangMSayreJLassmanCEffect of vessel size on creation of hepatic radiofrequency lesions in pigs: assessment of the heat sink effect. AJR Am J Roentgenol. 2002;178 (1):47–51.
19.
HakiméAHines-PeraltaAPeddiHCombination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology. 2007;244 (2):464–470.
20.
MertensJCMartinIVSchmittJMultikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. Eur J Radiol. 2012;81 (7):1601–1606.
21.
BruixJTakayamaTMazzaferroVet al;STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16 (13):1344–1354.
22.
ColagrandeSInghilesiALAburasSTalianiGGNardiCMarraFChallenges of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22 (34):7645–7659.
23.
ChenLSunJYangXRadiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status. Cancer Lett. 2016;370 (1):78–84.
24.
ZengJLvLMeiZCEfficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials. Clinics and research in hepatology and gastroenterology. 2016.
